` ARX (Aroa Biosurgery Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

ARX
vs
S&P/ASX 300

Over the past 12 months, ARX has underperformed S&P/ASX 300, delivering a return of -11% compared to the S&P/ASX 300's 6% growth.

Stocks Performance
ARX vs S&P/ASX 300

Loading

Performance Gap
ARX vs S&P/ASX 300

Loading
ARX
S&P/ASX 300
Difference

Performance By Year
ARX vs S&P/ASX 300

Loading
ARX
S&P/ASX 300
Add Stock

Competitors Performance
Aroa Biosurgery Ltd vs Peers

S&P/ASX 300
ARX
ABBV
AMGN
GILD
VRTX
Add Stock

Aroa Biosurgery Ltd
Glance View

Market Cap
151.8m AUD
Industry
Biotechnology

Aroa Biosurgery Ltd. engages in the development of products for wound care and soft tissue regeneration. The firm is engaged in commercializing regenerative tissue substitutes for medical conditions where impaired healing leads to serious consequences for patients. The company designs and manufactures medical products which enable surgeons and clinicians to repair serious tissue injuries. The Company’s solutions include Endoform platform, Wound Care Portfolio and Reinforced Bioscaffolds. The Endoform platform is a building block for developing a range of regenerative tissue substitutes to assist with tissue repair and healing. Its wound care products comprise extracellular matrix to manage acute and chronic wounds. The Reinforced Bioscaffolds combine the biologics and synthetics to address the surgical ventral hernia repair solutions.

ARX Intrinsic Value
1.16 AUD
Undervaluation 62%
Intrinsic Value
Price
Back to Top